BetaGlue Therapeutics
PrivateLast Round
VC Round
Dec 16, 2024
Total Funding Raised
$15.57M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
BetaGlue Therapeutics is an oncology company developing YntraDose, a radiotherapy platform designed for the localized and targeted treatment of unresectable solid tumours.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BetaGlue Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
BetaGlue Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Dec 16, 2024 | ||||
| Grant | Mar 4, 2024 | ||||
| VC Round | Jul 28, 2022 | ||||
| Series A | Sep 7, 2016 |
Key People
Founding team and executive leadership
BetaGlue Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant, VC Round |
| Neva SGR | VC Round |
| Fondazione ENEA Tech | VC Round |
| Innogest Capital | VC Round |
| Fin Posillipo S.p.A. | VC Round |
| Kairos Partners SGR | VC Round |
| Panakès Partners | VC Round, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 16, 2026
Monthly visitors grew 101% MoM, reaching 1K.
- Sep 22, 2025
Alexis Peyroles appointed as the new Chief Executive Officer.
BetaGlue Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about BetaGlue Therapeutics's valuation, stock price, and market status.